van Jaarsveld B C, Krijnen P
Department of Internal Medicine, Erasmus University Hospital Rotterdam, The Netherlands.
Semin Nephrol. 2000 Sep;20(5):463-73.
This prospective multicenter study included 1,205 patients, who were referred for difficult-to-treat hypertension or analysis of possible secondary hypertension. After a standardized selection protocol based on sharply defined drug-resistant hypertension or renal function impairment during angiotensin-converting enzyme inhibition, patients underwent renal scintigraphy and a captopril-renin challenge test. A set of clinical characteristics was also recorded. Sensitivity and specificity of renal scintigraphy for diagnosing renal artery stenosis were 0.72 and 0.90 and of the captopril-renin test 0.77 to 0.91 and 0.69 to 0.75 depending on the criterion used. The clinical characteristics were used to construct a clinical prediction rule for renal artery stenosis, which had a sensitivity of 0.68 and a specificity of 0.87 at a cut-off level of 30% predicted probability. However, with the prediction rule a sensitivity of 0.90 could be reached by performing arteriography only in patients with a predicted probability of stenosis of > or =10%, resulting in a considerable reduction of the number of arteriograms to be made. A diagnostic strategy is advocated starting with drug-resistant hypertension and continuing to renal arteriography only in patients with increased probability of stenosis. Patients with atherosclerotic renal artery stenosis were then randomized to balloon angioplasty (n = 56) versus antihypertensive medication (n = 50). Three months after randomization 22 patients from the medication group underwent balloon angioplasty in second instance. In an intention-to-treat analysis, no difference in blood pressure was found between the groups after 3 months, nor after 12 months of follow-up, although there was a small medication-sparing effect of balloon angioplasty. The lack of a beneficial effect of balloon angioplasty compared with medication could not be attributed to the high stenosis recurrence rate after angioplasty, nor to the fact that the inclusion criterion was set at a stenosis level of > or =50% so that patients with relatively mild stenosis were also included. Renal function after angioplasty was slightly better in the angioplasty group than in the medication group, and improvement of the renal scintigram occurred more often after angioplasty. Apart from the treatment of patients with specific characteristics, the presented therapeutic approach starts with extending the antihypertensive drug therapy to control blood pressure. Only if blood pressure cannot be controlled or if renal function deteriorates, balloon angioplasty (with stent placement) is indicated.
这项前瞻性多中心研究纳入了1205例患者,这些患者因难治性高血压或可能的继发性高血压而被转诊。在基于明确界定的耐药性高血压或血管紧张素转换酶抑制期间的肾功能损害制定标准化选择方案后,患者接受了肾闪烁显像和卡托普利-肾素激发试验。还记录了一组临床特征。根据所使用的标准,肾闪烁显像诊断肾动脉狭窄的敏感性和特异性分别为0.72和0.90,卡托普利-肾素试验的敏感性为0.77至0.91,特异性为0.69至0.75。利用临床特征构建了肾动脉狭窄的临床预测规则,在预测概率截断水平为30%时,其敏感性为0.68,特异性为0.87。然而,采用该预测规则,仅对预测狭窄概率≥10%的患者进行血管造影,可使敏感性达到0.90,从而显著减少血管造影的数量。提倡一种诊断策略,从耐药性高血压开始,仅对狭窄可能性增加的患者继续进行肾动脉造影。然后将动脉粥样硬化性肾动脉狭窄患者随机分为球囊血管成形术组(n = 56)和抗高血压药物治疗组(n = 50)。随机分组3个月后,药物治疗组的22例患者再次接受了球囊血管成形术。在意向性分析中,3个月后两组之间的血压无差异,随访12个月后也无差异,尽管球囊血管成形术有轻微的减少药物用量的作用。与药物治疗相比,球囊血管成形术缺乏有益效果,这既不能归因于血管成形术后狭窄复发率高,也不能归因于纳入标准设定为狭窄水平≥50%,从而纳入了相对轻度狭窄的患者。血管成形术后,血管成形术组的肾功能略优于药物治疗组,血管成形术后肾闪烁显像改善的情况更常见。除了对具有特定特征的患者进行治疗外,所提出的治疗方法首先是延长抗高血压药物治疗以控制血压。只有在血压无法控制或肾功能恶化时,才考虑进行球囊血管成形术(并置入支架)。